P rimary use of coronary stents to reduce restenosis after coronary angioplasty in simple lesions is well supported by major clinical trials. 1, 2 Use of stents in complex lesions, although now routine, has not been subjected to equal scrutiny.
Nonacute occlusions are complex not only from the occlusion itself but also from the frequent coexistence of extended length, contiguous diffuse disease, and thrombus. The late results of balloon angioplasty (PTCA) for coronary occlusions are poor. 3 Their tendency to reocclude may prompt selection of surgical revascularization or medical therapy as initial treatment. Importantly, the failure of angioplasty to provide a high rate of sustained patency has hindered trials testing routine late recanalization of infarct-related arteries (the "open-artery" hypothesis). 4 Although stenting of highly selected simple coronary occlusions can improve results, it is untested in larger, broadly selected cohorts. 5, 6 We report final angiographic and 6-month clinical outcomes from a controlled randomized trial testing the heparin-coated Palmaz-Schatz stent (Cordis, Johnson & Johnson) in a diverse spectrum of patients with nonacute coronary occlusions.
Methods

Participating Centers and Sponsorship
The Total Occlusion Study of Canada (TOSCA) was a multicenter prospective randomized controlled trial of primary stenting in native coronary artery occlusions conducted at 18 centers in accordance with local institutional guidelines after review board approval (Appendix 1). Study design and rationale have been reported previously. 7 The primary purpose was to determine whether routine stent placement improves late complete patency (TIMI flow grade 3) of recanalized coronary artery occlusions. The protocol was developed and implemented by the investigators and supported by a grant from Cordis, Johnson & Johnson.
Patient Selection
Patients 18 to 80 years old undergoing clinically indicated coronary interventions were eligible provided that 1 target segment met the study definition of occlusion: a high-grade native coronary stenosis accompanied by TIMI grade 0 or 1 antegrade flow. The target segment was required to be able to accommodate a balloon of Ն3.0-mm diameter and to be suitable for stent placement. Exclusion criteria were (1) Ͻ72 hours since onset of ST-segment elevation, (2) extensive lesion-related thrombus (TIMI thrombus grade 3 or 4, Appendix 2), (3) occlusions previously revascularized by patent bypass grafts, (4) uncontrolled heart failure or shock, (5) patient unwilling or unsuitable for protocol-required 6-month angiography, (6) patient of child-bearing potential, and (7) inability to cross occlusion with guidewire. All patients provided written informed consent.
Age of occlusion was determined by the interval from the last episode of acute coronary syndrome or infarction consistent with the location of the occlusion. Randomization, stratified by center and age of occlusion (Յ6 weeks or Ͼ6 weeks/uncertain) occurred after the occlusion was crossed with a guidewire but before initial dilation. Patients undergoing attempted recanalization of coronary occlusions but not enrolled were entered into a previously reported registry. 7 
Clinical Care and Monitoring
Operators were instructed to optimize PTCA results using a balloon of Ն3.0-mm nominal diameter and a balloon-to-artery ratio of Ն1. Prolonged inflations of Ն15 minutes' duration were required before crossover to stent. However, because significant residual stenosis and dissection frequently characterize initial PTCA results in occlusions but seldom result in acute ischemic events, crossover was recommended only if a Ն70% visual stenosis or major dissection causing impaired flow or ischemia (chest pain or ECG changes) was present. 7, 8 The stent arm used the Carmeda process heparin-coated 15-mmlong PS-153 Palmaz-Schatz coronary stent premounted on a sheathed delivery system. 9 Complete coverage of the occluded segment and adjacent lesion was required, using as many contiguous stents as necessary. Stent expansion at Ն14 bar was recommended.
Treatment of lesions in major segments proximal or distal to the occlusion with Ͼ50% visual stenosis was required in both arms. Use of stents in noncontiguous lesions or other vessels was not determined by protocol. All patients received aspirin 325 mg/d beginning before the procedure. Ticlopidine administration was left to operator discretion.
Clinical events and ECGs were routinely recorded at 24 hours, hospital discharge, 1 month, and final angiography. Creatine kinase (CK) and CK-MB were obtained at baseline, 8 hours, and 18 to 24 hours after the procedure.
Angiographic Analysis
After intracoronary nitroglycerine, Ն2 orthogonal views were reproduced at baseline, after the initial procedure, and at final 6-month angiography. Angiograms performed before 6 months qualified as final if (1) failure of patency was present, (2) the interval from enrollment to angiography was Ͼ16 weeks, or (3) the findings led to target-vessel bypass grafting.
Analysis of lumen dimensions and flow was performed independently in a dedicated core laboratory using the ImageCom system (Quinton). Target lesion work length, defined as the length of contiguous target segment exposed to balloon inflation, was measured by use of images recorded throughout the procedure. 7 Minimum lumen diameter (MLD) was derived from analysis of the entire treated segment. With rigorously selected disease-free proximal-only reference segments used, restenosis was defined as Ͼ50% diameter stenosis at the point of MLD. Reference values were deemed unmeasurable in ostial and near-ostial occlusions.
End Points
Failure of sustained complete target-vessel patency at final angiography, defined as TIMI flow Ͻ3 as determined by the Core Angiographic Laboratory, was the primary end point. To prevent counting of nonepicardial causes of reduced flow, an accompanying target-vessel stenosis of Ͼ70% was also required. Target segment MLDs and restenosis rates were secondary end points.
Clinical end points were (1) repeat target-vessel revascularization (TVR, defined as any attempted percutaneous or surgical revascularization of the target vessel after the initial procedure) and (2) a composite end point composed of any revascularization (of any coronary vessel), myocardial infarction (MI), or death. MI was defined as any CK-MB elevation above local laboratory normal range and was classified according to the magnitude of peak CK-MB elevation (Յ5 times or Ͼ5 times normal). A 3-member committee adjudicated all events.
Data Analysis
All end-point analyses were performed on an intention-to-treat basis. Prespecified subgroups included patients with age of occlusion Յ6 weeks versus Ͼ6 weeks (or uncertain) and baseline TIMI flow grade 0 versus 1. Discrete variables are provided as counts and percentages and compared by 2-tailed Fisher's exact test. Normally distributed continuous variables are expressed as meanϮSD, and abnormally distributed continuous variables as medians with interquartile ranges.
Results
From March 1996 through May 1997, 1118 patients were screened for inclusion. 7 Of these, 380 (34%) did not meet eligibility criteria (including 101 excluded for inability to cross with a guidewire), 328 (29%) were eligible but not enrolled, and 410 were enrolled. Baseline characteristics of the treatment groups were well matched (Tables 1 and 2 ).
Treatment Variables
Median target lesion work length was 30.5 mm (range, 20.9 to 43.7 mm) ( Table 3) . Crossover during the initial procedure occurred in 20 patients (9.6%) assigned to PTCA and 8 (4.0%) assigned to stent. On average, 2.0 contiguous target lesion stents were deployed per stent-assigned patient. Both operator-estimated reference vessel diameter and mean nominal balloon size were similar in the 2 groups, although maximum inflation pressures were higher in stent patients. Use of abciximab was infrequent (3%). Apart from ticlopi- dine, which was administered more frequently to stent patients (93% versus 57%, PϽ0.01), discharge medications were similar.
Clinical Outcome
By final angiography, TVR had occurred in 15.4% of patients assigned to PTCA and 8.4% assigned to stent, a relative reduction of 45% (Pϭ0.03, Figure 1 , Tables 4 and 5) . TVR rates diverged early after the index procedures. No instances of acute or subacute stent thrombosis were apparent. Composite adverse cardiac event rates were similar (23.6% PTCA versus 23.3% stent, PϭNS). Although a trend toward reduced revascularization of any vessel was seen in the stent group, more MIs occurred in this group. The majority of infarctions, however, were characterized by peak CK-MB elevations of Յ5 times normal, and none resulted in new Q waves. None of the 20 patients who experienced MI in the periprocedural period (4 PTCA, 16 stent) suffered recurrent MI or death during follow-up. No cardiac deaths occurred.
Patency and Quantitative Angiography
Angiographic follow-up was obtained in 392 patients (95.6%), refused in 15 (6 PTCA, 9 stent), and not possible in 3 (1 PTCA, 2 stent). At final angiography, each reduced TIMI flow grade (0, 1, or 2) was observed less frequently in the stent group than in the PTCA group (Table 6) . Therefore, failure to sustain patency was present in 21 of 191 patients assigned to stent (10.9%) versus 39 of 201 patients assigned to PTCA (19.5%), a 44% relative reduction (Figure 2) . Although operator-estimated mean vessel size, targetsegment location, and final mean balloon size were very similar in PTCA and stent patients, core laboratory-determined mean baseline proximal reference diameters were 0.16 mm larger in stent patients. However, no relationship Values are n (%). *Operator determined, before crossover. †Ͻ50% residual MLD stenosis and TIMI grade 3 flow by core laboratory in target vessel without crossover, repeat revascularization, any MI, or death before hospital discharge.
between this variable and failed patency was present on univariate or multivariate logistic modeling.
Initial postprocedural and final follow-up MLDs were significantly larger in the stent group, despite greater late loss (Table 7, Figure 3 ). Angiographic restenosis (Ͼ50% diameter stenosis) derived by use of proximal reference segments was present in 55% of patients assigned to stent and 70% assigned to PTCA (PϽ0.01).
Discussion
Reocclusion after PTCA of symptomatic coronary occlusions is reported in 16% to 34% and restenosis in 45% to 72%. 3, 5, 6, 10, 11 Results in asymptomatic patients from preliminary open-artery trials have been equally discouraging. In the Total Occlusion Post-MI Intervention Study (TOMIIS), for example, sustained patency was achieved in just 43% of the intervention arm. 12 In the wake of nonrandomized reports, 13-15 2 randomized trials of stents in coronary occlusions with Ն100 patients have been published. Both the Stents in Chronic Coronary Occlusion (SICCO) and Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche (GISSOC) trials evaluated stents in highly selected populations excluding long lesions, other complex features, and patients with recent infarction. 5, 6 Both demonstrated that stents reduce restenosis (32% versus 72% and 32% versus 68%, respectively). GISSOC also demonstrated reduced reocclusion with stents (8% versus 34%), although only stent patients received routine warfarin therapy.
Enrollment criteria for TOSCA were much broader. Patients with long occlusions, occlusions contained within diffuse segments of disease, moderate lesion-related thrombus, recent infarction, and other complex features that might diminish the effectiveness of stents were not excluded. Unlike SICCO and GISSOC, randomization occurred immediately after the guidewire was advanced across the occlusion. Thus, operators were committed to enrollment and treatment assignment before initial dilation permitted detailed assessment 
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of target segment length, distal vessel quality or dissection, or unrecognized thrombus. The choice of failed patency as the primary end point was based on several considerations. First, because failed patency occurs less frequently than restenosis, only a study powered to detect improved patency would be adequately powered to examine both. Second, the significance of angiographic restenosis in vessels previously occluded is unclear, given the inevitability of previous downstream infarction, developed collaterals, or both. Third, because strong circumstantial evidence links patency (but not restenosis) to improved post-MI outcome, prospective trials testing the open-artery hypothesis await therapies proven to enhance sustained patency. 4, 16 Our primary end-point results are clear. Compared with PTCA, stenting of occluded coronary arteries results in a marked improvement in sustained patency. Primary end-point results in the 4 prespecified subgroups, although they demonstrate heterogeneity of the point estimate, are compatible with general benefit. CIs cross unity only in subgroups with Ͻ150 patients.
Stenting, however, did not eliminate patency failures. Nearly 11% of patients assigned to stenting demonstrated failed patency, and 8.3% (versus 13.5% of PTCA patients, Pϭ0.15) developed complete reocclusion (TIMI 0 or 1 flow). New stent designs and periprocedural or long-term glycoprotein IIb/IIIa antagonists may have roles yet to be defined. Interestingly, patients assigned to PTCA had lower rates of failed patency than previously reported, despite inclusion of complex lesions, rigorous crossover rules, and low crossover rates.
Restenosis
Our convention of using disease-free proximal reference segments as the sole denominator for all quantitative analyses was driven by the inability to obtain distal reference segments in occluded vessels. Given the natural taper of coronary arteries, this approach would be expected to increase percent stenosis values compared with analyses using interpolated references. Nevertheless, we observed large values of absolute late loss in both arms attributable to the additive effects of large initial gain, extended lesion length, thrombus, and frequent use of multiple stents. [17] [18] [19] Furthermore, although PTCA restenosis rates in TOSCA, SICCO, and GISSOC were remarkably similar, we found less difference in stent and PTCA restenosis rates in our complex population, despite the possible advantage conveyed by slightly larger proximal reference segments in the stent arm. As with patency, stents with greater length and improved uniformity of radial support may prove particularly effective in this challenging setting. 17, 20 
Target-Vessel Revascularization
In contrast to previous studies, stenting reduced TVR before the confounding effect of protocol-specified angiography. 1, 2, 6 The immediate divergence of the curves is consistent with previous observations that early reocclusion is common. 8 Overall, TVR was infrequent (11.9%), despite frequent angiographic restenosis. However, some stable patients may have had repeat revascularization deliberately delayed pending protocol angiography. Continued follow-up is therefore essential to determine the durability of our 6-month findings.
Adverse Cardiovascular Events
Although composite adverse cardiac event rates were similar in the stent and PTCA groups, certain patterns emerged. Revascularization procedures in any vessel tended to be more frequent in the PTCA group. This trend, however, was driven entirely by procedures involving the target segment ( Table 5) .
As defined in the protocol, MI was more frequent in the stent group (11.9% versus 3.8%, Pϭ0.01). We screened for periprocedural MI with routine sequential enzyme samples and used a very inclusive definition (any elevation of CK-MB, regardless of total CK). Most MIs were indeed periprocedural and small. The mechanisms for periprocedural infarction after coronary occlusion angioplasty are enigmatic. Early closure of the target lesion is probably not responsible; both early TVR and late failed patency were more common in the treatment group with fewer MIs. More likely, distal thromboembolism or obstruction of side branches arising near target occlusions accounts for this phenomenon. The significance of small periprocedural CK-MB elevations after stent placement is controversial. [21] [22] [23] Regardless, recent data suggest that routine use of abciximab would have largely abolished group differences in rates of periprocedural infarction. 24 
Other Limitations
Although our angiographic follow-up rate was high, 4.4% of the study population was not reevaluated angiographically. A conservative remedy would be to impute the overall combined rate of failed patency (15.3%) to all patients without final angiography. This approach does not, however, materially affect our results (Pϭ0.03).
As in other device trials, treatment assignment could not readily be blinded. Thus, a bias influencing subsequent patient management could have existed. The study design does not permit conclusions regarding the importance of the heparin coating of the investigational stents. Similarly, our study did not address occlusions that cannot be crossed with a guidewire, a difficulty encountered in 9% of patients screened for TOSCA.
Summary
We have demonstrated that primary stent placement improves late patency and reduces restenosis in a broadly selected population with occluded coronary arteries. Stenting resulted in a reduced need for repeat TVR but no net difference in overall adverse cardiac events. Although continued clinical follow-up is necessary, these data support routine stenting when occluded coronary arteries are reopened. In contrast to previous stent trials, TOSCA had few criteria to exclude lesions perceived as unfavorable. These data, therefore, provide new insights regarding the utility of stents in the treatment of complex lesions frequently encountered in current practice.
